Publikationen (ab 2010)

Generation of unexpected allele-specific anti-HLA antibodies after the transplantation of a fully matched kidney allograft. Its impact on the exclusion of subsequent renal regrafts only identifiable through the use of patient's high resolution HLA-typing and corresponding single antigen antibody specification. Schlaf G., Kehlen J., Wahle A., Mauer D. and Altermann W.
zur Veröffentlichung eingereicht

Solid phase-based cross-matching for solid organ transplantation: Currently out-of-stock but urgently required for improved allograft outcome. Schlaf G., Bau D., Horstmann N., Sawers G. and Altermann W.
Histol. Histopathol. 35 (2020), 937-948.

Is periodontitis a prognostic factor in order to indicate antibodies against citrullinated peptides in patients with rheumatoid arthritis? Reichert, S., Jurianz, E., Natalie, P., Schlumberger, W., Dähnrich, C., Johannsen, N., Altermann, W., Schlaf, G., Keyßer, G., Schäfer, C., Schaller, H.G. and Schulz, S.
Clin. Exp. Rheumatol. 38 (2020), 227-238.

Solid phase-based cross-matching using the luminex platform for solid organ allo-grafting: Rather regression than progress in comparison to the ELISA-based precursor procedure. Bau, D., Sawers, G., Wahle, A., Altermann, W. and Schlaf, G.
J. Clin. Cell. Immunol. 10 (2019), DOI: 10.4172/2155-9899.1000576; Epub 2019 Apr 26th

Strong humoral anti-HLA immune response upon arbitrarily chosen allogeneic arterial vessels. Konrad, H., Wahle, A., Altermann, W. and Schlaf, G.
J. Clin. Cell. Immunol. 8 (2017), DOI: 10.4172/2155-9899.1000525; Epub 2017 Oct 23rd

Differences in the frequencies of HLA-class I and II alleles between German patients with renal cell carcinoma and healthy controls. Goebel, S., Kehlen, A., Bluemke, K., Altermann, W., Schlaf, G., Fischer, K., Fornara, P., Wullich, B., Wach, S. and Taubert H.
Cancer Immunol. Immunother. (2017), DOI 10.1007/s00262-017-1957-3; Epub 2017 Febr 9th

Basiliximab: Well-established as an immunosuppressive therapeutic antibody, but falsifying the outcome of lymphocytotoxicity-based standard cross-matching. Schlaf, G. and Altermann, W.
Buchbeitrag für: Basiliximab: Indications, Contraindications and adverse effects. Editor: Leon V. Berhardt, Chapter 5 / ID 45615 (2017): 96-113, NOVA Science Publishers Inc., New York, USA

Der Festphasen-Kreuztest als valides diagnostisches Werkzeug zum Nachweis falsch positiver Kreuztestresultate bei Patienten mit begleitenden Autoimmun-erkrankungen [Solid phase-based cross-matching as a valid tool to detect false positive CDC-based crossmatch results in recipients with accompanying autoimmune diseases]. Schlaf, G., Rothhoff, A. and Altermann, W.
Transfusionsmedizin 6 (2016): 169-173 (DOI 10.1055/s-0042-114209)

ELISA-based cross-matching allowing the detection of emerging donor-specific anti-HLA antibodies through the use of stored donors‘ cell lysates. Schlaf G., Stöhr K., Rothhoff A. and Altermann W.
Case Rep. Transplant. (2015), 763157; Epub 2015 Oct 15th

Detection of post-transplant anti-HLA donor-specific antibodies through the use of stored donors’ cell lysates and solid phase-based cross-matching. Schlaf G., Pistorius I. and Altermann W.
J. Clin. Cell. Immunol. (2015), 6; 1000383, Epub 2015, Dec 31st

Solid phase-based cross-matching in order to avoid kidney allografting against donor-specific anti-HLA antibodies: Long term experience with a procedure allowing highly reliable diagnoses. Schlaf G., Pollok-Kopp B. and Altermann W.
Austin J. Nephrol. Hypertens. (2014), 1(6) 9-18.

Solid phase-based cross-matching as solution for kidney allograft recipients pretreated with therapeutic antibodies. Schlaf G., Apel S., Wahle A. and Altermann W.
BioMed Res. Int. (2015);587158, Epub 2015, Jan 15th

Systemic Lupus Erythematosus leading to terminal renal failure and excluding patients from kidney allocation due to inadequate CDC-based cross-matching: Is there a way out? Schlaf G., Rothhoff A. and Altermann W.
J. Clin. Cell. Immunol., Buchbeitrag für Sonderband “Systemic Lupus Erythema-tosus”, Editor Kaihong Su, Nebraska Medical Center Omaha 5 (2014), 198-206.

Sensitive solid-phase detection of donor-specific antibodies as an aid highly relevant to improving allograft outcomes.
Schlaf G., Pollok-Kopp B. and Altermann W.
Mol. Diagn. Ther. (2014), 18, 185-201.

Individual composition of human leukocyte antigens and periodontopathogens in the background of periodontitis. Reichert S., Altermann W., Stein J.M., Schaller H.G. and Schulz S.
J. Periodontol. (2013), 84 (1), 100-109.

Artificially positive crossmatches not leading to the refusal of kidney donations due to the usage of adequate diagnostic tools. Schlaf G., Pollok-Kopp B.,
Schabel E. and Altermann W.
Case Rep. Transplant. (2013), 746395, Epub March 28th

Improved detection of donor-specific anti-HLA antibodies and increased reliability of pre- and post-transplant cross-matching relevant for organ allograft survival through the use of novel solid phase-based assays. Schlaf G., Pollok-Kopp B. and Altermann W. Buchbeitrag für “Organ Donation and Organ Donors: Issues, Challenges and Perspectives”; Editor Reza F. Saidi, Nova Science Publishers, Inc., New York, USA; Buchedition im Jahr 2013

Hodgkin’s lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responses. Winkler C., Steingrube D.S., Altermann W., Schlaf G., Max D., Kewitz S., Emmer A., Kornhuber M., Banning-Eichenseer U. and Staege M.S.
Cancer Immunol. Immunother. (2012), 61, 1769-1779.

General insufficiency of the classical CDC-based crossmatch to detect donor-specific anti-HLA antibodies leading to invalid results under recipients’ medical treatment or underlying diseases. Schlaf G., Mauz-Körholz C., Ott U., Leike S. and Altermann W.
Histol. Histopathol. (2012), 27, 31-38.

Generation of donor-specific anti-HLA antibodies after the transplantation of a fully-matched kidney allograft. Impact on the selection of a subsequent renal regraft. Schlaf G., Radam C., Wahle A. and Altermann W.
Transplant. Proc. (2012), 44, 1442-1445.

A novel ELISA-based crossmatch procedure to detect donor-specific anti-HLA antibodies responsible for corneal allograft rejections. Sel S. / Schlaf G.,
Schurat O. and Altermann W.
J. Immunol. Methods (2012), 381, 23-31.

Novel solid phase-based ELISA assays contribute to an improved detection of anti-HLA antibodies and to an increased reliability of pre- and post-transplant crossmatching. Schlaf G., Pollok-Kopp B., Manzke T., Schurat O. and Altermann W.
Nephrol. Dial. Transplant. PLUS (2010), 3, 527-538.